Breakthrough in Antibiotic Safety: IIT Bombay's Membrane Tracking Method
Researchers at the Indian Institute of Technology Bombay (IIT Bombay) have unveiled a groundbreaking approach to predict antibiotic toxicity by tracking how these drugs interact with liver cell membranes. This innovation addresses a critical challenge in pharmacology: why some antibiotics, despite similar chemical structures and efficacy against infections, cause severe liver damage while others do not. Led by Prof. Ashutosh Kumar from the Department of Biosciences and Bioengineering, the team collaborated with experts from Sunway University in Malaysia to demonstrate that the location and duration of antibiotic accumulation in hepatocyte plasma membranes—the outer layers of liver cells—serve as reliable early indicators of drug-induced liver injury (DILI).
The study, published in the journal Biochimica et Biophysica Acta (BBA) - Biomembranes, challenges conventional wisdom that toxicity stems primarily from the degree of membrane rupture. Instead, it highlights subtle differences in drug-membrane topology. "Traditionally, people believed that a drug molecule's harm to cells comes from how much it ruptures the cell membrane. Our results can change that view," Prof. Kumar explained.
This development is particularly timely for India, where antibiotic overuse fuels antimicrobial resistance (AMR) and contributes to rising DILI cases, often linked to anti-tuberculosis drugs and other antimicrobials.
Understanding Drug-Induced Liver Injury: A Growing Concern
Drug-induced liver injury (DILI) remains one of the leading causes of acute liver failure worldwide and a primary reason for drug withdrawals post-approval. In India, DILI accounts for about 10% of acute-on-chronic liver failure cases, with anti-tuberculosis (anti-TB) drugs implicated in nearly 50% of instances, followed by complementary and alternative medicines (13-27%) and antimicrobials (6-17%). Antibiotics like amoxicillin-clavulanate, cotrimoxazole, and glycopeptides frequently appear in reports, exacerbating the burden amid high self-medication rates and polypharmacy.
The liver, as the body's primary detox organ, processes over 90% of therapeutic drugs via hepatocytes. These cells feature complex plasma membranes rich in lipids and proteins essential for transport, signaling, and metabolism. Disruptions here can trigger inflammation, enzyme elevation (e.g., ALT, AST), and progression to fibrosis or failure. Traditional prediction relies on animal models or late-stage trials, but early biomarkers are lacking, leading to costly failures—estimated at $2-3 billion per drug globally.
In the Indian context, with over 2.6 million TB cases annually and widespread antibiotic misuse, hepatotoxicity poses a public health crisis. The IIT Bombay method offers a paradigm shift toward proactive screening.
The IIT Bombay Research Team Driving Innovation
At the helm is Prof. Ashutosh Kumar, whose lab at IIT Bombay's Biosciences and Bioengineering Department specializes in membrane biophysics and drug delivery. First author Akash Kumar Jha, a PhD candidate, led experiments, emphasizing the membrane as "the first point of contact between a drug and liver cells." Co-authors Raj Gupta and Arabinda Saha contributed biophysical analyses, while Prof. Vetriselvan Subramaniyan from Sunway University brought expertise in glycopeptide pharmacology.
IIT Bombay's interdisciplinary ecosystem, bolstered by facilities like the High-Field NMR (750 MHz), Isothermal Titration Calorimetry (ITC), Differential Scanning Calorimetry (DSC), Dynamic Light Scattering (DLS), and Cryo-TEM—funded by the Research and Innovation Facilitation Cell (RIFC) and Industrial Research and Consultancy Centre (IRCC)—enabled this work. Such infrastructure positions IIT Bombay as a hub for translational bioengineering research in India.Explore research positions at leading Indian institutes like IIT Bombay.
Step-by-Step: The Innovative Methodology
The team employed a multi-modal approach:
- Artificial Membrane Models: Constructed lipid bilayers mimicking hepatocyte plasma membranes using phospholipids like phosphatidylcholine and phosphatidylethanolamine.
- Biophysical Assays: DLS tracked aggregation; cryo-TEM visualized structural changes like clumping and fusion; ITC/DSC measured thermodynamic interactions.
- Spectroscopy and Simulations: High-resolution NMR pinpointed drug localization (surface vs. core); molecular dynamics (MD) simulations modeled anchoring mechanisms.
- In Vivo Validation: Rat models dosed with antibiotics assessed liver enzymes (ALT/AST), histopathology, and inflammation markers.
This integrated pipeline revealed Teicoplanin's preference for the membrane-aqueous interface, forming stable surface complexes that alter charge and lipid dynamics, versus Oritavancin's deep bilayer insertion.
"Teicoplanin sticks to the membrane surface, changing the surface charge and how the outer lipid layer is packed and moves," Jha noted.
Key Findings: Surface vs. Deep Localization
Teicoplanin and Oritavancin, lipoglycopeptides for gram-positive infections (e.g., MRSA, pneumonia), differ clinically: Teicoplanin links to higher hepatotoxicity. Despite less disruption, Teicoplanin induced elevated enzymes, inflammation, and damage in rats. Its surface adsorption causes chronic stress on membrane proteins. Oritavancin, perturbing more structurally, embeds deeply, minimizing interference.
- Topology over magnitude: Prolonged interface interactions predict toxicity.
- Thermodynamics: Drug-specific profiles via ITC/DSC.
- Simulations: Confirmed anchoring—surface for Teicoplanin, core for Oritavancin.
Highlights from the paper underscore a "lipid-centric framework" for safer drugs.Read the full study.
Comparing with Existing Toxicity Prediction Tools
Current methods include QSAR models, machine learning classifiers (e.g., RF, MLP for DILI concern), and in vitro hepatocyte assays. However, they overlook membrane topology. IIT Bombay's biophysical tracking complements AI-driven predictions (e.g., ToxinPred for peptides) by providing mechanistic insights at the molecular level, scalable for high-throughput screening.
In India, where computational toxicology lags, this lab-based technique bridges gaps, integrable with ICMR efforts on AMR.
Tips for academic CVs in computational biology.Implications for Drug Development and Patient Safety
This method enables pre-clinical flagging of risky candidates, reducing DILI failures. For pharma giants like Sun Pharma or Dr. Reddy's, it streamlines pipelines. In hospitals, it informs stewardship amid India's 70% AMR rates for key pathogens.
Benefits:
- Cost savings: Avoid $1B+ late-stage failures.
- Safer alternatives: Modify surface-binding drugs.
- Regulatory edge: Align with CDSCO, USFDA DILI guidelines.
"These tests are relatively fast and scalable," Jha affirmed.IIT Bombay Research Highlight.
India's Antibiotic Crisis: Context and Urgency
India consumes 13% of global antibiotics, with 50-80% misuse driving hepatotoxicity. ATT causes 46% DILI; non-TB antibiotics 6.5%. ICMR reports underscore need for prediction tools amid 1.3M annual TB deaths.
IIT Bombay's work supports NAP-AMR, fostering university-pharma ties.Higher ed opportunities in India.
Future Directions and Broader Applications
Extending to other classes (e.g., beta-lactams), AI integration for simulations, clinical trials for validation. Potential in personalized medicine via membrane profiling.
IIT Bombay eyes spin-offs; Prof. Kumar's lab recruits for MD/NMR expertise.
Cultivating Talent: Careers in Membrane Biophysics at IITs
Aspiring researchers can pursue PhDs/MS in bioengineering at IIT Bombay, leveraging SERB funding. Skills: Biophysics, MD sims, imaging. Job prospects in pharma R&D, academia.Research assistant roles abundant.
"Our results shift the focus... helping explain why some drugs harm the liver more," Prof. Kumar.Postdoc success guide.
Outlook: Safer Antibiotics for a Healthier India
IIT Bombay's innovation heralds safer drugs, curbing DILI in high-burden settings. Explore Rate My Professor, higher ed jobs, career advice, university jobs, or post a job at AcademicJobs.com.